Skip to main content

Table 5 Percentage differences between active and placebo groups at different time points

From: Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]

Parameter

3/6 months (n = 1417)

1 year (n = 1156)

2 years (n = 917)

3 years (n = 723)

Total cholesterol

7.7 (6.7–8.7)

8.4 (7.0–9.7)

7.8 (6.3–9.3)

8.1 (6.3–9.9)

HDL-cholesterol

10.6 (8.9–12.2)

9.4 (7.2–11.6)

7.3 (5.1–9.6)

6.2 (3.3–9.1)

LDL-cholesterol

9.2 (7.5–10.9)

9.4 (7.2–11.6)

8.1 (5.6–10.6)

9.3 (6.1–12.5)

Triglycerides

23.0 (20.1–25.9)

23.3 (19.6–27.1)

25.4 (21.2–29.7)

23.4 (18.3–28.5)

Fibrinogen

12.4 (10.8–13.9)

14.4 (12.4–16.3)

14.2 (11.9–16.5)

13.2 (10.6–15.9)

Creatinine

13.1 (11.8–14.3)

13.2 (11.7–14.7)

11.6 (9.8–13.4)

9.4 (7.1–11.6)

Alkaline phosphatase

30.6 (29.0–32.1)

33.5 (29.5–37.6)

33.4 (30.6–36.3)

32.3 (29.3–35.2)

  1. Percentage differences (95% confidence intervals) between active and placebo groups at 3/6 months (average), 1 year, 2 years and 3 years. For statistical methods, see text. All group differences were significant, at P < 0.0001.
Back to article page

Trials

ISSN: 1745-6215